Author: Emily R. Gabranski
Editor: Jeff T. Watson
In Ariosa Diagnostics, Inc. v. Sequenom, Inc., Nos. 14-1139, -1144 (Fed. Cir. Dec. 2, 2015), the Federal Circuit denied Sequenom’s petition for a rehearing en banc of the panel’s decision that Sequenom’s asserted claims were patent ineligible under 35 U.S.C. § 101. The order was accompanied by two concurring opinions and one dissenting opinion.
In his concurring opinion, where he was joined by Judge Moore, Judge Lourie agreed with the panel’s application of Mayo Collaborative Services. v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012), but expressed concerns about the Mayo test itself. Judge Lourie wrote that Sequenom’s claims “should not be patent-ineligible on the ground that they set forth natural laws or are abstractions,” but rather “the finer filter of § 112 might be better suited to treating these as questions of patentability.” Similarly, in his concurring opinion, Judge Dyk voiced concern that “a too restrictive test . . . may discourage development and disclosure of new diagnostic and therapeutic methods in the life sciences.”
In contrast, Judge Newman disagreed with the panel’s application of Mayo, writing in her dissenting opinion: “Precedent does not require that all discoveries of natural phenomena or their application in new ways or for new uses are ineligible for patenting.” Judge Newman also stated that the facts of Ariosa “diverge significantly” from the facts and rulings of Mayo.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.